Authors: R Teggi B Colombo O Gatti G Comi M Bussi
Publish Date: 2015/06/03
Volume: 36, Issue: 10, Pages: 1869-1873
Abstract
Vestibular migraine VM is one of the most frequent causes of episodic vertigo with a lifetime prevalence of 098 Prophylactic therapy includes calcium channel blockers betablockers antiepileptic drugs and antidepressants We studied the association of cinnarizine 20 mg and dimenhydrinate 40 mg Arlevertan© in a group of 22 patients affected by definite VM Proposed therapy included one tablet twice a day for 1 month which was repeated three times with 1 month of interval between drug intake results were compared with those of a control group of 11 VM patients who asked to observe only lifestyle measures for migraine The main outcome was the number of vertigo and headache crises in the 6 months before therapy and in the 6 months of followup Subjects performing Arlevertan© presented during the 6 months of therapy a decrease of vertigo attacks from 53 to 21 and of headaches from 43 to 17 p 00001 68 of these subjects reported a decrease of at least 50 of vertigo attacks while 63 of headaches Conversely vertigo attacks decreased from 35 to 22 and headaches from 26 to 2 in patients observing only lifestyle 18 of these subjects reported a decrease of at least 50 of vertigo crises and 27 of headaches Our data do not differ from those of previous works assessing efficacy of different prophylactic therapies for VM and reporting consistent reduction of vertigo spells in a rate of patients ranging from 60 and 80
Keywords: